Breaking down BIOSECURE—Industry implications and what comes next

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. 

In this week's episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner sits down with Arnold & Porter’s Life Sciences practice chair Dan Kracov to discuss the broader implications of the bill, and what the likely next steps are for the legislation to become law. 

Kracov also breaks down what measures life sciences companies are already taking in light of the bill and concessions that may need to be made to appease lawmakers on both sides of the aisle.  

To learn more about the topics in this episode: 

• After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned
• Despite looming BIOSECURE threat, pharma contracting giant WuXi Bio scoops up new projects
• Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

See omnystudio.com/listener for privacy information.